A pre-revenue biotech firm focused on developing FDA-cleared biosensors for continuous physiological monitoring with a substantial capital reserve but currently operating at a loss.
Investors might consider the stock based on the company's substantial paid-in capital of $26.6 million which provides runway for product development without immediate revenue pressure. The potential for a breakthrough in non-invasive glucose monitoring represents a high-reward opportunity if the company can successfully commercialize its biosensor platform.
The stock carries extreme risk due to zero revenue, a massive accumulated deficit of $29.1 million, and negative cash flow that has depleted current assets to just $7,000. With liabilities nearly 136 times greater than total assets, the company faces a high probability of dilution or insolvency before achieving commercial viability.
Non-Invasive Monitoring Systems Inc. develops and commercializes advanced biosensors for continuous physiological monitoring, primarily serving the healthcare and consumer wellness markets. Despite recent revenue stagnation, the company maintains a significant paid-in capital base to support its research and development initiatives in non-invasive glucose and other metabolic monitoring technologies.
The company reported a net loss of $222,000 in 2025, continuing a trend of profitability challenges with losses of $222,000 in 2023 and $160,000 in operating profit. Cash flow from operations remained negative at $117,000 while cash reserves decreased by $22,000 year-over-year, resulting in a current cash position of only $3,000 against total liabilities exceeding $950,000.
The non-invasive monitoring industry is experiencing rapid growth driven by demand for continuous health tracking and remote patient monitoring solutions from aging populations. While the sector offers significant long-term potential, early-stage companies often struggle to bridge the gap between technology development and profitable commercialization.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $169.0K | $59.0K | $160.0K |
| Operating Income | $-169.0K | $-59.0K | $-160.0K |
| G&A | $169.0K | $177.0K | $160.0K |
| Other OpEx | $0 | $-118.0K | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $30.0K | $54.0K | $62.0K |
| Pre-Tax Income | $-169.0K | $-59.0K | $-160.0K |
| Income Tax | $31.0K | $54.0K | $62.0K |
| Continuing Ops | $-200.0K | $-113.0K | $-222.0K |
| Discontinued Ops | $1.0K | $0 | $0 |
| Net Income | $-199.0K | $-113.0K | $-222.0K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-199.0K | $-113.0K | $-222.0K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $23.0K | $34.0K | $7.0K |
| Cash & Equivalents | $7.0K | — | — |
| Other Current Assets | $16.0K | — | — |
| Long-Term Assets | $0 | $0 | $0 |
| Total Assets | $23.0K | $34.0K | $7.0K |
| Current Liabilities | $291.0K | $161.0K | $954.0K |
| Accounts Payable | $209.0K | $80.0K | $99.0K |
| Other Current Liab | $82.0K | $81.0K | $855.0K |
| Long-Term Liabilities | $344.0K | $598.0K | $0 |
| Total Liabilities | $635.0K | $759.0K | $954.0K |
| Shareholders' Equity | $-612.0K | $-725.0K | $-947.0K |
| Paid-In Capital | $26.6M | $26.6M | $26.6M |
| Retained Earnings | $-28.7M | $-28.8M | $-29.1M |
| Total L&E | $23.0K | $34.0K | $7.0K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-199.0K | $-113.0K | $-222.0K |
| Non-Cash Adjustments | $10.0K | $14.0K | $10.0K |
| Working Capital Changes | $31.0K | $-83.0K | $95.0K |
| Cash from Operations | $-158.0K | $-182.0K | $-117.0K |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $150.0K | $200.0K | $95.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-8.0K | $18.0K | $-22.0K |
| Beginning Cash | $15.0K | $7.0K | $25.0K |
| Ending Cash | $7.0K | $25.0K | $3.0K |
The company operates primarily through the development and licensing of its proprietary biosensor technology, targeting segments in diabetes management, respiratory disease monitoring, and general metabolic health tracking without generating current product revenue.
Total absence of current revenue streams leading to persistent operating losses and cash burn; significant accumulated deficit of over $29 million indicating historical financial distress; high reliance on external financing to sustain operations given the negative cash flow from operations; and potential regulatory hurdles in bringing new biosensor products to market.
Proprietary non-invasive sensor technology capable of measuring multiple biomarkers simultaneously; a strong intellectual property portfolio providing regulatory clearance advantages; and a robust capital structure with $26.6 million in paid-in capital to fund long-term R&D cycles.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.